Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens
Vishal J. Sindhava, … , Ann Marshak-Rothstein, Michael P. Cancro
Vishal J. Sindhava, … , Ann Marshak-Rothstein, Michael P. Cancro
Published March 27, 2017
Citation Information: J Clin Invest. 2017;127(5):1651-1663. https://doi.org/10.1172/JCI89931.
View: Text | PDF
Research Article Immunology

A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens

  • Text
  • PDF
Abstract

Mature B cell pools retain a substantial proportion of polyreactive and self-reactive clonotypes, suggesting that activation checkpoints exist to reduce the initiation of autoreactive B cell responses. Here, we have described a relationship among the B cell receptor (BCR), TLR9, and cytokine signals that regulate B cell responses to DNA-containing antigens. In both mouse and human B cells, BCR ligands that deliver a TLR9 agonist induce an initial proliferative burst that is followed by apoptotic death. The latter mechanism involves p38-dependent G1 cell-cycle arrest and subsequent intrinsic mitochondrial apoptosis and is shared by all preimmune murine B cell subsets and CD27– human B cells. Survival or costimulatory signals rescue B cells from this fate, but the outcome varies depending on the signals involved. B lymphocyte stimulator (BLyS) engenders survival and antibody secretion, whereas CD40 costimulation with IL-21 or IFN-γ promotes a T-bet+ B cell phenotype. Finally, in vivo immunization studies revealed that when protein antigens are conjugated with DNA, the humoral immune response is blunted and acquires features associated with T-bet+ B cell differentiation. We propose that this mechanism integrating BCR, TLR9, and cytokine signals provides a peripheral checkpoint for DNA-containing antigens that, if circumvented by survival and differentiative cues, yields B cells with the autoimmune-associated T-bet+ phenotype.

Authors

Vishal J. Sindhava, Michael A. Oropallo, Krishna Moody, Martin Naradikian, Lauren E. Higdon, Lin Zhou, Arpita Myles, Nathaniel Green, Kerstin Nündel, William Stohl, Amanda M. Schmidt, Wei Cao, Stephanie Dorta-Estremera, Taku Kambayashi, Ann Marshak-Rothstein, Michael P. Cancro

×

Figure 1

Addition of BLyS prevents AM14 and WT B cells from undergoing proliferation-associated cell death following stimulation with BCR-delivered TLR9 ligands.

Options: View larger image (or click on image) Download as PowerPoint
Addition of BLyS prevents AM14 and WT B cells from undergoing proliferat...
Representative FACS analysis at 60 hours (A) and percentage of live divided cells at 48, 60, and 72 hours (C) in AM14 CD23+ splenocytes cultured with the indicated stimuli in the presence or absence of BLyS. Dead cells were stained with TO-PRO-3, while CFSE dilution indicates proliferation. (B and D) Representative FACS analysis at 60 hours (B) and percentage of live divided cells at 48, 60, and 72 hours (D) in C57BL/6 CD23+ splenocytes cultured with the indicated stimuli in the presence or absence of BLyS. Diagram in B (inset) depicts the structure of STIC9. (E and F) Representative FACS analysis at 60 hours (E) and percentage of live divided cells 60 hours after STIC9 stimulation (F) in C57BL/6 and Tlr9–/– CD23+ B cells. (G) Immunoblot analysis of p-SYK in protein extracts isolated from CD23+ C57BL/6 splenocytes cultured with the indicated stimuli. Fold-change differences in expression are shown compared with unstimulated cells. Values in parentheses indicate the molecular weight. (H) FACS analysis of B cells from Nur77-GFP reporter mice at 5 hours, cultured with the indicated stimuli, with or without TLR9 inhibitor (Inh18) as described previously (84). Gray-filled area represents no stimulation; black line represents F(ab′)2 fragments of anti-IgM; gray line represents ODN 1826; blue line represents F(ab′)2 fragments of anti-IgM plus ODN 1826; and red line represents STIC9. Max, maximum. (I) Representative FACS plots show the proliferation and survival of C57BL/6 CD23+ splenocytes cultured for 60 hours with SA-linked biotinylated (Bio) ODN 1826 and biotinylated F(ab)2, in the presence or absence of BLyS. Data represent a minimum of 3 independent experiments with 3 mice each. Error bars indicate the mean ± SEM. *P < 0.05 and ***P < 0.001, by 2-tailed Student’s t test. “–” signifies unstimulated cells.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts